Abstract
There are currently limited data on the epidemiology, clinical manifestations, and optimal management of Coronavirus Disease 2019 (COVID-19) in hematopoietic cell transplantation and cellular therapy recipients. Given the experience with other respiratory viruses, we anticipate that patients may develop severe clinical disease and thus provide the following general principles for cancer centers across the nation. These guidelines were developed by members of the American Society for Transplantation and Cellular Therapy Infectious Diseases Special Interest Group. Specific practices may vary depending on local epidemiology and testing capacity, and the guidance provided in this document may change as new information becomes available.
Keywords: COVID-19; SARS-CoV-2; cellular therapy; hematopoietic cell transplan.
【저자키워드】 COVID-19, SARS-CoV-2, cellular therapy, hematopoietic cell transplan., 【초록키워드】 coronavirus disease, Coronavirus disease 2019, therapy, Infectious diseases, Epidemiology, Local, Infectious disease, respiratory viruses, clinical manifestations, management, Patient, respiratory, group, information, Guidance, cellular, Other respiratory viruses, Hematopoietic cell transplantation, transplantation, cell transplantation, Society, Cancer center, recipients, nation, clinical disease, Specific, interest, Cell, develop, provided, 【제목키워드】 guideline, recipient, hematopoietic,